Cedric Francois - 21 Jul 2021 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Executive Officer, Director
Signature: /s/David Watson, attorney-in-fact for Cedric Francois
Issuer symbol: APLS
Transactions as of: 21 Jul 2021
Net transactions value: +$62,107
Form type: 4
Filing time: 22 Jul 2021, 16:04:55 UTC
Next filing: 10 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Options Exercise	$62,107	+14,410	+1.2%	$4.31^*	1,234,243	21 Jul 2021	Direct
holding	APLS	Common Stock						234,411	21 Jul 2021	See Footnote	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Options Exercise	$0	-14,410	-3.7%	$0.000000	375,538	21 Jul 2021	Common Stock	14,410	$4.31	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities are held by The Francois-DuBois Educational Trust (the "Trust"), for which the Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.
F2	This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.